B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9

B of A Securities analyst Jason Zemansky has maintained a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ: RCKT) and raised the price target from $8 to $9.